MPM BioImpact LLC reported 36 positions worth $1.30B for the quarter ended Sep 30, 2026, down 19.8% on the prior quarter. It opened 9 new positions, added to 8, trimmed 18 and exited 9. Its largest holding is Cullinan Therapeutics, Inc. at 11.5% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| IOVA Iovance Biotherapeutics, Inc. | +2.84M | – | $42.03M | 3.24% |
| IMCR Immunocore Holdings plc | +1.20M | – | $36.45M | 2.81% |
| VIR Vir Biotechnology, Inc. | +2.81M | – | $31.41M | 2.42% |
| VSTM Verastem, Inc. | +3.85M | – | $31.01M | 2.39% |
| ODTX Odyssey Therapeutics, Inc. | +1.29M | – | $28.64M | 2.2% |
| ORKA Oruka Therapeutics, Inc. | +300.0K | – | $24.99M | 1.92% |
| ACRS Aclaris Therapeutics, Inc. | +4.14M | +396.7% | $21.75M | 2.1% |
| NGNE Neurogene Inc. | +771.8K | – | $21.47M | 1.65% |
| DYN Dyne Therapeutics, Inc. | +1.29M | +66.9% | $20.72M | 3.98% |
| TSHA Taysha Gene Therapies, Inc. | +2.76M | +61.4% | $13.46M | 2.72% |
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| RVMD Revolution Medicines, Inc. | -492.5K | -100.0% | $92.23M | Exited |
| ALMS Alumis Inc. | -2.02M | -100.0% | $56.82M | Exited |
| RARE Ultragenyx Pharmaceutical Inc. | -1.42M | -100.0% | $47.35M | Exited |
| DNTH Dianthus Therapeutics, Inc. | -420.0K | -100.0% | $40.94M | Exited |
| CORT Corcept Therapeutics Inc | -349.0K | -45.3% | $40.22M | 3.74% |
| MLTX MoonLake Immunotherapeutics | -1.61M | -100.0% | $31.29M | Exited |
| SNDX Syndax Pharmaceuticals Inc | -1.33M | -100.0% | $29.15M | Exited |
| TRDA Entrada Therapeutics, Inc. | -1.25M | -100.0% | $9.22M | Exited |
| DBVT DBV Technologies S.A. | -621.6K | -17.0% | $7.31M | 2.76% |
| TVTX Travere Therapeutics, Inc. | -34.4K | -3.1% | $2.02M | 4.93% |
| Holding | Shares | Trade Value | Weight |
|---|---|---|---|
| IOVA Iovance Biotherapeutics, Inc. | +2.84M | $42.03M | 3.24% |
| IMCR Immunocore Holdings plc | +1.20M | $36.45M | 2.81% |
| VIR Vir Biotechnology, Inc. | +2.81M | $31.41M | 2.42% |
| VSTM Verastem, Inc. | +3.85M | $31.01M | 2.39% |
| ODTX Odyssey Therapeutics, Inc. | +1.29M | $28.64M | 2.2% |
| ORKA Oruka Therapeutics, Inc. | +300.0K | $24.99M | 1.92% |
| NGNE Neurogene Inc. | +771.8K | $21.47M | 1.65% |
| CRBP Corbus Pharmaceuticals Holdings, Inc. | +1.67M | $11.37M | 0.875% |
| TRAX First Tracks Biotherapeutics, Inc. | +254.4K | $9.02M | 0.694% |
| Holding | Shares Sold | Trade Value | Prior Weight |
|---|---|---|---|
| RVMD Revolution Medicines, Inc. | -492.5K | $92.23M | 5.7% |
| ALMS Alumis Inc. | -2.02M | $56.82M | 3.51% |
| RARE Ultragenyx Pharmaceutical Inc. | -1.42M | $47.35M | 2.92% |
| DNTH Dianthus Therapeutics, Inc. | -420.0K | $40.94M | 2.53% |
| MLTX MoonLake Immunotherapeutics | -1.61M | $31.29M | 1.93% |
| SNDX Syndax Pharmaceuticals Inc | -1.33M | $29.15M | 1.8% |
| TRDA Entrada Therapeutics, Inc. | -1.25M | $9.22M | 0.57% |
| CNTX Context Therapeutics Inc. | -1.30M | $719.54K | 0.044% |
| HOWL Werewolf Therapeutics, Inc. | -80.1K | $28.85K | <0.01% |
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | CGEM Cullinan Therapeutics, Inc. | Healthcare | 9.72M | $149.22M | 11.49% | -10.3K | -0.1% | Reduced | 14.98% |
| 2 | AKTS Aktis Oncology, Inc. | Healthcare | 4.84M | $94.15M | 7.25% | 0 | 0.0% | Unchanged | 8.69% |
| 3 | TVTX Travere Therapeutics, Inc. | Healthcare | 1.09M | $64.08M | 4.93% | -34.4K | -3.1% | Reduced | 1.14% |
| 4 | EWTX Edgewise Therapeutics, Inc. | Healthcare | 1.58M | $63.99M | 4.93% | -44.8K | -2.8% | Reduced | 1.44% |
| 5 | DYN Dyne Therapeutics, Inc. | Healthcare | 3.21M | $51.68M | 3.98% | +1.29M | +66.9% | Added | 1.71% |
| 6 | CORT Corcept Therapeutics Inc | Healthcare | 422.0K | $48.63M | 3.74% | -349.0K | -45.3% | Reduced | 0.39% |
| 7 | RLAY Relay Therapeutics, Inc. | Healthcare | 2.37M | $42.77M | 3.29% | -46.1K | -1.9% | Reduced | 1.08% |
| 8 | TRVI Trevi Therapeutics, Inc. | Healthcare | 2.98M | $42.66M | 3.28% | -94.7K | -3.1% | Reduced | 1.86% |
| 9 | IOVA Iovance Biotherapeutics, Inc. | Healthcare | 2.84M | $42.03M | 3.24% | +2.84M | – | New | 0.61% |
| 10 | LQDA Liquidia Corp | Healthcare | 1.34M | $40.63M | 3.13% | -43.5K | -3.1% | Reduced | 1.5% |
| 11 | NTRA Natera, Inc. | Healthcare | 90.6K | $37.44M | 2.88% | -2,053 | -2.2% | Reduced | 0.06% |
| 12 | URGN UroGen Pharma Ltd. | Healthcare | 909.7K | $36.96M | 2.85% | -23.7K | -2.5% | Reduced | 1.8% |
| 13 | IMCR Immunocore Holdings plc | Healthcare | 1.20M | $36.45M | 2.81% | +1.20M | – | New | 2.33% |
| 14 | DBVT DBV Technologies S.A. | Healthcare | 3.04M | $35.81M | 2.76% | -621.6K | -17.0% | Reduced | 3.38% |
| 15 | TSHA Taysha Gene Therapies, Inc. | Healthcare | 7.26M | $35.37M | 2.72% | +2.76M | +61.4% | Added | 1.79% |
Tip. Select a row to see that position’s full history at MPM BioImpact.
As of its Q3 2026 13F filing, MPM BioImpact LLC’s five largest positions were Cullinan Therapeutics, Inc. (CGEM) at 11.5%, Aktis Oncology, Inc. (AKTS) at 7.2%, Travere Therapeutics, Inc. (TVTX) at 4.9%, Edgewise Therapeutics, Inc. (EWTX) at 4.9%, Dyne Therapeutics, Inc. (DYN) at 4.0% of the reported portfolio.
MPM BioImpact LLC reported a 13F portfolio worth $1.30B across 36 positions for Q3 2026. That is down 19.8% from the previous quarter.
Its largest purchases by value were Iovance Biotherapeutics, Inc. ($42.03M), Immunocore Holdings plc ($36.45M), Vir Biotechnology, Inc. ($31.41M). It opened 9 new positions.
Its largest sales by value were Revolution Medicines, Inc. ($92.23M), Alumis Inc. ($56.82M), Ultragenyx Pharmaceutical Inc. ($47.35M). It exited 9 positions entirely.
From the Form 13F-HR reports MPM BioImpact LLC files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.